艾迪康控股(09860.HK)擬收購元德維康及元德友勤全部股權
格隆匯5月6日丨艾迪康控股(09860.HK)公告，於2025年5月6日，公司、杭州艾迪康、賣方及目標公司（元德維康及元德友勤）就收購目標公司全部股權訂立投資協議。根據投資協議，(i)公司已有條件同意向賣方甲收購於元德維康的全部股權，代價爲191.0百萬港元，其將以配發及發行最多2903萬股代價股份（相當於本公告日期公司已發行股本總額約4%及經代價股份擴大的公司已發行股本總額約3.85%）支付；及(ii)杭州艾迪康已有條件同意向賣方乙收購於元德友勤的全部股權，現金代價爲人民幣5000萬元。
於收購事項完成後，(i)元德維康將由公司直接或間接全資擁有；及(ii)元德友勤將由杭州艾迪康直接全資擁有及將鑑於合約安排入賬列爲公司的附屬公司。
杭州艾迪康爲集團ICL業務在中國的控股公司。透過合約安排，公司控制並持有杭州艾迪康100%的經濟利益，杭州艾迪康及其附屬公司在中國經營ICL業務。
元德友勤爲一家於中國成立的有限公司，專門從事醫學檢驗服務，擁有血液檢測專業知識。元德維康爲一家於中國成立的有限公司，專注於血液診斷試劑的研發及生產。
收購事項爲一項戰略投資，與集團的既定戰略一致，即憑藉其在ICL行業的領導地位，並透過瞄準其他醫療檢測服務供應商及把握具重大發展潛力市場的增長機遇，擴大其服務網絡。收購事項的主要理據是有機會實現有意義的能力擴展及垂直整合。收購元德友勤（專門從事醫學檢驗服務，擁有血液檢測專業知識）將使集團深化其專業知識並拓寬其在ICL市場高價值血液學檢測的服務組合。這與集團現有的綜合測試服務相輔相成，強化了集團的市場定位。同時，收購元德維康（其從事於血液診斷試劑的研發及生產）是邁向垂直整合的關鍵一步。收購事項將爲集團提供內部研發及製造能力，提供供應鏈安全及專有診斷技術。該等能力預計將增強集團的創新能力、提高運營效率及差異化其服務產品。此外，收購事項亦引入陳軍先生及岑建農先生（長德維康的普通合夥人）等關鍵人員，彼等於臨牀測試服務的豐富行業經驗將爲集團貢獻寶貴的人力資本及特定領域的知識。
完成收購事項的預期利益涉及多層面並具有重大的戰略意義。具體而言，(i)整合元德友勤的專業診斷服務預期將大幅鞏固集團作爲中國領先的綜合ICL服務提供商的地位；(ii)加入元德維康的試劑開發及生產能力，增強集團的差異化及競爭優勢；及(iii)透過元德維康建立內部研發及製造職能預期將提高長期供應鏈控制及運營效率。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
